Sign in
Taking people in United StatesNo phase

Comparing transplant and standard treatment for children with sickle cell disease

Compares stem cell transplant with ongoing disease-modifying medicines in children with sickle cell disease.

Key facts

Who runs it
University of Rochester
Where
Atlanta, Birmingham, Boston, Buffalo, Chapel Hill, Charlotte, Chicago, Columbus, Hackensack, Houston, Indianapolis, Memphis, New York, Oklahoma City, Philadelphia, Queens, Rochester, San Antonio, St Louis, The Bronx, Washington D.C., and Wilmington, United StatesSee the 31 sitesAlso in 1 other country, 6 sites
Trial code
Registry title
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
Status
Recruiting
People taking part
480 people, planned
Started
1 Jun 2024
Expected to end
1 Oct 2030
Type of study
Observational, 2 groups
Record updated
4 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people aged 3 to 20.9 years with sickle cell anemia. Some are planning a stem cell transplant from a related donor; others take non-transplant disease-modifying treatment.

Age
3 to 20.9 years
Sex
All sexes
Disease stage
Sickle cell anemia (HB SS or HBSB0 Thalassemia).
Earlier treatment
Transplant group: candidates for a stem cell transplant from a related donor with a compatible tissue type. Other group: already receiving non-transplant disease-modifying therapy.

Main reasons for not taking part

  • Younger than 3 years or older than 20.9 years
  • No sickle cell anemia or related condition
  • Transplant group: cannot have the transplant or has no related donor with a compatible tissue type
  • Enrolled in another trial that might interfere with this study
  • Cannot follow the study plan or the follow-up visits

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Pediatric patients aged between 3 and 20.9 years
  • Children diagnosed with sickle cell Anemia (HB SS or HBSB0 Thalassemia)
  • For the MRD HCT group, children who are candidates for matched related donor hematopoietic stem cell transplantation (MRD HCT)
  • For the NT-DMT group, children who are receiving non-transplant disease-modifying therapies (NT-DMT) for SCD
  • Participants (or their guardians) must provide informed consent to be part of the study
  • Participants must be willing to undergo the necessary assessments and follow-up visits over the 3-year study period

Who cannot take part

  • For the MRD HCT group, children who are not eligible for the transplant or do not have a matched related donor
  • Children who do not have sickle cell anemia or related conditions
  • Children younger than 3 years or older than 20.9 years
  • Children who are currently enrolled in other clinical trials that might interfere with the WeDecide study
  • Children who are unable to adhere to the study protocol or follow-up requirements

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 3 and 20 years old?

Where in United States

Also in 1 other country, 6 sites

  • Children's Healthcare of Atlanta (MRD-HCT)Atlanta, United StatesContact: Judith TalibTaking people
  • Children's of Alabama (MRD-HCT)Birmingham, United StatesContact: Jana HilburnTaking people
  • Children's of Alabama (NT-DMT)Birmingham, United StatesContact: Jeanine DumasNot yet recruiting
  • Boston Children's Hospital (MRD-HCT)Boston, United StatesContact: Lydia L OsuagwuTaking people
  • Boston Children's Hospital (NT-DMT)Boston, United StatesContact: Nadia TarhiniNot yet recruiting
  • Roswell Park (MRD-HCT)Buffalo, United StatesContact: Stephanie GuilfordTaking people
  • UNC Children's Hospital (MRD HCT)Chapel Hill, United StatesContact: Juanita CufeeNot yet recruiting
  • UNC Children's Hospital (NT-DMT)Chapel Hill, United StatesContact: Lindsey AkpuoguNot yet recruiting
  • Atrium Health (MRD-HCT)Charlotte, United StatesContact: Marithza AmayaTaking people
  • Comer Children's Hospital (MRD-HCT)Chicago, United StatesContact: Christopher OmahenTaking people
  • Nationwide Children's Hospital (NT-DMT)Columbus, United StatesContact: Anthony VillelaNot yet recruiting
  • Hackensack University Hospital (MRD-HCT)Hackensack, United StatesContact: Elana SmilowTaking people
  • Texas Children's Hopsital (NT-DMT)Houston, United StatesContact: Daniela WesterholdNot yet recruiting
  • Texas Children's Hospital (MRD-HCT)Houston, United StatesContact: Helton D. Cruz RivasTaking people
  • Riley Children's Hospital (MRD-HCT)Indianapolis, United StatesContact: Courtney SpiegelTaking people
  • Riley's Children Hospital (NT-DMT)Indianapolis, United StatesContact: Jillian BouckNot yet recruiting
  • St Jude Children Hospital (NT-DMT)Memphis, United StatesContact: Jason HodgesNot yet recruiting
  • St. Jude Children's Research Hospital (MRD-HCT)Memphis, United StatesContact: Stacy HighTaking people
  • Columbia Presbytarian (NT-DMT)New York, United StatesContact: Nikhil PunwaniNot yet recruiting
  • Oklahoma Children's Hospital (MRD-HCT)Oklahoma City, United StatesContact: Christina GonzalezNot yet recruiting
  • Children's Hospital of Philadelphia (MRD-HCT)Philadelphia, United StatesContact: Peter NicholasTaking people
  • Cohen's Children Hospital (NT-DMT)Queens, United StatesContact: Ferdausi ShifathNot yet recruiting
  • University of Rochester (MRD-HCT)Rochester, United StatesContact: Savannah PangrazioNot yet recruiting
  • University of Rochester (NT-DMT)Rochester, United StatesContact: Savannah PangrazioNot yet recruiting
  • UT San Antonio (NT-DMT)San Antonio, United StatesContact: Sophia Isabel SalinasNot yet recruiting
  • Wahington Univ in St Louis (NT-DMT)St Louis, United StatesContact: Bethany KelloggNot yet recruiting
  • Washington University in St Louis (MRD-HCT)St Louis, United StatesContact: Ian SnyderNot yet recruiting
  • Children's Hospital at Montefiore (MRD HCT)The Bronx, United StatesContact: Elaine ChungNot yet recruiting
  • Children's Hospital at Montefiore (NT-DMT)The Bronx, United StatesContact: Karen IrelandTaking people
  • Children's National Hospital (MRD-HCT)Washington D.C., United StatesContact: Julia MalloyTaking people
  • Nemours Children's Hospital, Delaware (MRD-HCT)Wilmington, United StatesContact: Megan PetrickTaking people

About the trial

What the trial wants to find out

The WeDecide study is a large observational study comparing the long-term effects of matched related donor hematopoietic stem cell transplantation (MRD HCT) and non-transplant disease-modifying therapies (NT-DMT) for pediatric patients with sickle cell disease (SCD). The study aims to assess health-related quality of life (HRQoL), cognitive function, risks, and benefits of both treatments, including survival rates, chronic complications, and organ damage prevention. With 160 children in the MRD HCT group and 320 in the NT-DMT group, aged 3-20.9 years, the study will follow participants for three years, examining factors like disease severity, treatment history, and social determinants of health. By providing a comprehensive comparison, the study seeks to inform clinical decisions and improve understanding of SCD treatment outcomes, ultimately supporting families and healthcare providers in choosing the best treatment options.

The 2 groups in the trial

  • NT-DMT Cohort

    This group includes 320 participants from U.S. and Canadian sites receiving non-transplant disease-modifying therapies, monitored annually over three years to assess health-related quality of life, cognitive function, disease progression, and healthcare utilization.

  • MRD HCT Cohort

    This group includes 160 participants from U.S. and Canadian sites receiving non-transplant disease-modifying therapies, monitored annually over three years to assess health-related quality of life, cognitive function, disease progression, and healthcare utilization.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease.
Plain-language title
Comparing transplant and standard treatment for children with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06941389, who can take part
Record updated
4 June 2026